To conclude, VPA is still the best investigated HDAC inhibitor for the treatment of human AML, both with regard to low-toxicity disease-stabilizing treatment and more intensive remission-inducing treatment. This evidence concerns the gene HDAC9 and acute myeloid leukemia.